POET Technologies (PTK: TSXV) (POETF: OTCQX) Vivek Rajgarhia, Thomas Mika and I discuss the success of their demos at the 2021 Optical Fiber Communication Conference and Exhibition (OFC) .
POET hosted a Gold-level sponsored booth showcasing the company’s latest news, products and video demonstrations.
Vivek describes the conference as an “inflection point” … and the smiles on their faces are hard to ignore!
Sit back and watch this powerful interview!
FEATURES June 7, 2021
Green Market Report covers our fiscal Q3 earnings in their Psychedellux recap of the top business stories in the psychedelic medicine industry.
Novamind reported total revenue of $1.8 million, a 43% quarter-over-quarter, driven by increased patient volume at the Company’s four operating clinics.
Novamind Launches Psychedelic Therapy Protocol for Frontline Healthcare Workers
“Together with the Wholeness Center, we’re joining forces to offer a new therapy that will positively impact the people who show up every day and continue to provide critical healthcare for the public during—and after—this difficult time,” said Dr. Robison.
Click here to learn more about the Frontline KAP protocol
June 10, 2021
The Brain-Changing Magic of New Experiences
From GQ’s series on mental health comes a piece about the psychological reasons how new experiences can change how we perceive time and make us more resilient. It’s an interesting read and the author even compares trees blooming in spring to psychedelics. “Even the most mundane new experiences left me feeling genuinely elated.” There’s a reason for it too. From Dr. Laurie Santos, “Novel stimuli tend to activate regions of our brain that are associated with rewards.” At our Cedar Psychiatry clinics, we practice a holistic approach to mental health. Taking into account psychological, biological, social, environmental, and cultural influences. Learn more here.
Atai Life Sciences Announces Launch of Initial Public Offering
We’ve always believed in Atai’s vision to transform the treatment of mental health disorders. It’s why we became early strategic investment partners. Congratulations to Atai Life Sciences on launching their initial public offering.
Follow @novamind_inc on Instagram
Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]
HPQ Silicon Resources $HPQ $HPQFF is a Quebec-based company that is developing a portfolio of high value-added silicon products sought after by battery and electric vehicle manufacturers.
If that sounds a lot like what other small companies are saying lately, $HPQ differentiates itself as a leader of the pack thanks to the following:
Today, the Company announced a major milestone with this press release HPQ Silicon GEN3 PUREVAP™ Quartz Reduction Reactor Pilot Plant to be Commissioned in Q4 2021
To discuss the importance and the implications of this milestone, this excerpt from the press release says it all:
” Demand for higher purity Silicon, materials that the PUREVAP QRR was designed to produce – but one that traditional silicon producers have a difficult time making, is about to enter a massive growth phase, driven by worldwide demand from the silicones, solar, and batteries industries. The Covid-19 pandemic accelerated the closing of old inefficient traditional Silicon plants and combining this with the chronic under investment in new conventional Silicon plants that occurred in the past decade, and the need for more efficient and environmentally friendly processes has created a perfect storm for the industry. HPQ should be a key beneficiary of this new reality.”
Watch this great interview with $HPQ CEO Bernard Tourillon to get the full picture on next steps!
When the Facebook data privacy scandal broke out, the world woke up to just how badly our individual data was being traded, used and most importantly, the amount of profit being generated by major corporations at our expense.
This led to the enactment of the biggest data privacy laws in history. Specifically, General Data Protection Regulation (GDPR) out of Europe and the California Consumer Privacy Act (CCPA).
Enter $LQID. The Company Turns The Problem Of Data Privacy Into A Profit For Individuals, While Providing Big Businesses With New & Compliant Business Models.
More than just lip service, $LQID has made some major announcements, including joining the Trust Over IP Foundation, which includes over 170 members including IBM, Mastercard, Accenture and many other global leaders who are defining a complete architecture for Internet-scale digital trust.
Does that sound like a mouthful? Yeah, it does. But all you have to really understand for now is that digital ID, privacy and monetization is going to become a reality in the very near future. Government regulations are enforcing it. Consumers are demanding it and $LQID is delivering it at such an advanced scale that the Trust Over IP Foundation provided them with a strategic role as a Steering Member.
If that wasn’t enough proof for you, Google validated the $LQID business model with this stunning announcement at the beginning of March:
What is the potential outcome of this major shift by Google?
“Google’s decision could upend the ad industry, which has relied on these types of tracking tools”
Now the data privacy and monetization game is underway with LQID sitting in a great position within the industry and the dominant position within the small cap world.
That dominant position got even stronger when $LQID announced Liquid Avatar Congratulates the Ontario Government on the Release of its Digital Strategy
WHY IS THIS SO IMPORTANT?
If consumers are going to switch to Liquid Avatar to protect and monetize their identity, the switch to Digital ID by Canada’s biggest Province is simply a monster catalyst: The Ontario government strategy outlines ways in which it plans to harness the potential of the digital economy and better utilize data. Included in the plan are tangible commitments such as:
Today, $LQID’s dominant position grew even stronger with the announcement Liquid Avatar Joins Linux Foundation Public Health Cardea Project. Why is this initiative so important?
Cardea is a complete ecosystem that can be used by public health authorities, governments, organizations, and industries to enable people to maintain their privacy while holding and using an easily verifiable, trustworthy, unalterable proof of a health test or vaccination.
One of the first projects to provide the related technology and guidance for implementation of the recently announced Global COVID Certificate Network (GCCN), also from Linux Foundation Public Health, Cardea helps facilitate the safe and free movement of individuals globally during the COVID pandemic.
Watch this interview with CEO David Lucatch for an even deeper discussion into what this all means for $LQID and YOU.
FEATURES June 4, 2021
At Novamind, we’re preparing for the future of psychedelic medicine, but we’re also treating people today and the results have been life changing.
“This is the first treatment that’s ever given me any relief from suicidal ideations. It’s like they’re gone.”
FEATURES June 1, 2021
Novamind CMO Reid Robison speaks to the Toronto Sun about why ketamine is a game changer for treating eating disorders.
“I was sitting with people before, during and after treatment and I was blown away by what I saw. It’s not just a treatment for depression.”
FEATURES June 2, 2021
Behavioral Healthcare Executive covers our fiscal Q3 earnings report, detailing growth and forecasted clinic visits.
“Novamind, a mental health company that specializes in psychedelic medicine, this week announced revenues of $1.85 million for its fiscal quarter ending March 31, a 43% increase over the prior quarter. With its previously announced plans to open 4 new clinics, doubling the size of its network, between July and September, Novamind said in its earnings report that it expects to increase patient volume to more than 65,000 clinic visits in 2021, which would represent a 225% increase year-over-year.”
Novamind Reports Fiscal Q3 Financial Results and Operating Highlights
“Since listing on the CSE this January, Novamind has demonstrated its ability to rapidly scale access to innovative mental health treatment and psychedelic medicine,” said Yaron Conforti, CEO and Director, Novamind. “The contract with Merck to research a promising new drug, leveraged our expertise in patient recruitment and patient management. Novamind will continue to execute on its aggressive growth initiatives in 2021, further expanding organically and through acquisitions ahead of the FDA’s anticipated approvals of MDMA and psilocybin.”
June 1, 2021
Researchers to Hone In On Most Therapeutic Doses of LSD
Identifying the correct dose for therapeutic settings is a crucial step in the path towards optimizing the healing power of psychedelics. In this article, Psychedelic Spotlight details new research studying the optimal LSD dosage for the treatment of mental health disorders. We look forward to more research and clinical trials in the future and will prepare for the time when LSD can be used as a treatment option in our clinics.
The psychologists signing up for psychedelic therapy training: ‘Amazing things can happen’
The promise of psychedelic medicine is too great to ignore for Campbell Townsend, an Australian-based psychologist who is training in psychedelic-assisted psychotherapy. The Australian government has recently committed $15m to psychedelic clinical trials and support is growing in that country. There is significant momentum growing. Staying at the forefront of psychedelic research, Novamind is currently developing protocols for ketamine-assisted psychotherapy that will standardize and provide best-practice treatment methods for the widespread use of psychedelic medicine.
Follow @novamind_inc on Instagram
Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]
As if today’s press release wasn’t good enough Empower Clinics Announces Major Expansion with Proposed Acquisition of Medisure Canada. Diabetes Tests and Devices Carried In 4,000 Pharmacies and Generated $1.9m in 2020 Revenue, shareholders also received this injection of confidence from CEO
Steve McAuley:
“As I’ve stated to our shareholders on multiple occasions throughout 2021, Empower is in the strongest position it has ever been and will continue to grow every aspect of our business unabated and without interruption. In addition to this acquisition, in the last 30 days alone we have announced expansions of our clinics, gone live on our KAI Saliva RT-PCR test with Air Canada and are very advanced on tripling the size of the KAI Medical Laboratory facility. We are hitting on all cylinders and well on our way to becoming a major vertically integrated healthcare company. I fully expect Empower to have continued strong business announcements in June and throughout 2021″
If that was all, it would be a great day … and it was with $CBDT closing up 16.5% on 7.5M shares to $0.53 … but then Steve shared some powerful information about leveraging this acquisition with large US pharmacies.
Who did he name?
Watch this great interview with CEO Steve McAuley.
Most of us know drones for their recreational uses or perhaps even as simple commercial applications for things like real estate videos.
But the fact of the matter is that drone usage is about to go parabolic with huge corporations adopting them for a wide-use of applications that most never dreamed of such as:
In short, the drone industry is booming in ways people can’t imagine because the industry is shifting from the drones themselves (hardware) to drone technology and solutions (software)… and the one company that is delivering the most challenging applications is DraganFly (DFLY: CSE) (DFLYF:OTCQB) (3U8:FSE)
DraganFly is an award-winning drone manufacturer and technology developer that is actually delivering some pretty incredible achievements, milestones and even history:
Clients include:
If you want ultra-cool consider that DFLY’s Vital Intelligence technology was selected for implementation by Knightscope, a leader in a leader in autonomous robot security capabilities.
All of this has translated into financial success with 2020 Revenue hitting $4.36M up 216% … and now a record Q1 with $1.53M up 210%.
With all of this under the Company’s belt, it’s easy to see why CEO Chell believes DFLY will become one of the top 2 drone companies in the world and why they near the end of the process of listing on NASDAQ.
If you believe in the massive parabolic growth in the use of drones for almost everything we do in this world, or want to learn, then watch / listen to this powerful interview with Draganfly CEO and Chairman, Cameron Chell.
When the Facebook data privacy scandal broke out, the world woke up to just how badly our individual data was being traded, used and most importantly, the amount of profit being generated by major corporations at our expense.
This led to the enactment of the biggest data privacy laws in history. Specifically, General Data Protection Regulation (GDPR) out of Europe and the California Consumer Privacy Act (CCPA).
Enter $LQID. The Company Turns The Problem Of Data Privacy Into A Profit For Individuals, While Providing Big Businesses With New & Compliant Business Models.
More than just lip service, $LQID has made some major announcements, including joining the Trust Over IP Foundation, which includes over 170 members including IBM, Mastercard, Accenture and many other global leaders who are defining a complete architecture for Internet-scale digital trust.
Does that sound like a mouthful? Yeah, it does. But all you have to really understand for now is that digital ID, privacy and monetization is going to become a reality in the very near future. Government regulations are enforcing it. Consumers are demanding it and $LQID is delivering it at such an advanced scale that the Trust Over IP Foundation provided them with a strategic role as a Steering Member.
If that wasn’t enough proof for you, Google validated the $LQID business model with this stunning announcement at the beginning of March:
What is the potential outcome of this major shift by Google?
“Google’s decision could upend the ad industry, which has relied on these types of tracking tools”
Now the data privacy and monetization game is underway with LQID sitting in a great position within the industry and the dominant position within the small cap world. That dominant position got even stronger today when $LQID announced Liquid Avatar updates Mobile App with Augmented Reality, initiates enterprise SaaS programs and approved for US trading
WHY IS THIS SO IMPORTANT?
$LQID is now ready to capitalize on all pipeline and future commercialization opportunities.Watch this great interview with CEO David Lucatch for an even deeper discussion into what this all means for $LQID and YOU.
Blockchain Foundry (BCFN:CSE) develops and commercializes blockchain-based business solutions and provides consulting services to corporate clients seeking to incorporate blockchain technology into their businesses.
The Company’s roadmap for the remainder of 2021 includes the development of a proprietary BCF wallet for holding Syscoin digital assets as well as Ethereum-based tokens and Bitcoin. Once this foundational wallet has been developed, the Company will continue to build blockchain-based infrastructure which plugs directly into the wallet.
Learn more by watching this powerful interview with Dan Wasyluk, CEO of Blockchain Foundry.
FEATURES May 28, 2021
Novamind COO Pierre Bou-Mansour discusses rapid expansion, staying consistent and Novamind’s ultimate goal.
“We want to set a new standard of mental healthcare, and be the network that patients prefer—to become a trusted partner for innovative mental healthcare.”
How a psychedelic 12-step program is saving lives
Focused on creating a safe space “to incorporate psychedelic medicine into recovery,” Dimitri M. is a living embodiment of the wounded healer. A former heroin addict whose life was changed by Ibogaine and a 12-step program. Since he’s gone on to form Psychedelics in Recovery and is holding up to 17 meetings a week over zoom. Access to psychedelic medicine in the right situation can be life-changing. Dr. Reid Robison calls psychedelics “therapy accelerators.” Learn more about our innovative approach to psychedelic medicine here.
MAPS wins appeal and authorization to study MDMA in healthy volunteer therapists
A study that had been on hold for almost two years has been approved. MAPS will hold a phase 1 clinical trial of MDMA-assisted therapy for healthcare workers. Working in conjunction with the FDA, MAPS was able to win the appeal and help “improve the regulatory landscape for all future patients of psychedelic-assisted medicines.” The study “will measure development of self-compassion, professional quality of life, and professional burnout among clinicians delivering the treatment to patients.” This study will address a critical area of need for healthcare workers.
Follow @novamind_inc on Instagram
Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]